scholarly journals Surgical component of lateral and central breast cancer treatment

2021 ◽  
Vol 102 (4) ◽  
pp. 479-485
Author(s):  
Z M Abdurakhmanova ◽  
M R Ramazanov ◽  
E I Sigal
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Oxygen Saturation ◽  
Cancer Treatment ◽  
Comparison Group ◽  
Breast Cancer Treatment ◽  
Main Group ◽  
Regional Lymph Nodes ◽  
Hemoglobin Oxygen Saturation ◽  
Arterial Blood

Aim. To improve the results of the surgical component in the treatment of a nodular form of breast cancer with lateral and central localization by analyzing hemoglobin oxygen saturation of arterial blood in the foci of breast cancer, regional lymph nodes and resection line of the breast. Methods. The study involved 175 patients with a nodular form of breast cancer with lateral and central localization (T23N12M0), including 86 in the main group and 89 in the comparison group. In the main group, hemoglobin oxygen saturation in arterial blood of the foci of breast cancer, parenchyma, pectoral muscles and regional lymph nodes was examined for spread of cancer during surgery for nodular breast cancer by using a device developed by us (patent RU 2581266). This examination was not performed in the comparison group. Histopathological examination of resection specimens revealed confirmation of the main foci of breast cancer and the presence of metastases in the regional lymph nodes and pectoral muscles of the breast. Statistical analysis of the data was performed by using the Statistica 10 software. The arithmetic mean, the standard error of the mean and the standard deviation were calculated for the quantitative indicators. Results. In the main group, 86 patients had no recurrence and metastases in the follow-up, while in the comparison group, cancer recurrence was identified in 89 patients and metastases was found during cytological and histological studies in 9 patients. Conclusion. Determination of hemoglobin oxygen saturation of arterial blood during surgery in the subclavian, axillary and subscapular lymph nodes as well as in the pectoralis major and minor muscles allows clarifying the distribution of breast cancer, specifying the scope of the operation and improving the results of the surgical component of breast cancer treatment (T23N12M0).

scholarly journals Value of Ultrasound in Evaluation of Abnormal Axillary Lymph Node

2021 ◽  
Vol 4 ◽  
pp. 3
Author(s):  
Abdelmohsen Radwan Hussien ◽  
Monaliza El-Quadi ◽  
Avice Oconnell
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cancer Treatment ◽  
Axillary Lymph Node ◽  
Breast Cancer Treatment ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph

Understanding of the various appearances of axillary lymph nodes (LNs) is essential for diagnosing and planning of breast cancer treatment. In this article, the role of ultrasound in detecting abnormal appearing metastatic LNs s is discussed, with emphasis on most of the ultrasonographic features and tools which might help improve detection of axillary LN pathology.

Impact of RxPONDER on breast cancer treatment in an academic-community hospital.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12524-e12524
Author(s):  
Be Saito ◽  
Cathryn Johnson ◽  
Lina Sizer ◽  
Catherine Carruthers ◽  
Elena Lamb ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Lymph Nodes ◽  
Cancer Treatment ◽  
Hormonal Therapy ◽  
Community Hospital ◽  
Breast Cancer Treatment ◽  
Academic Community ◽  
The Impact ◽  
Positive Lymph Nodes

e12524 Background: The introduction of Oncotype Dx set the stage for targeting chemotherapy treatment to only patients who would derive a benefit. RxPONDER trial then demonstrated that postmenopausal women with 1-3 positive lymph nodes, could forego chemotherapy if the recurrence score (RS) was ≤25. The most common chemotherapy regimens for breast cancer are taxotere and cytoxan or dose dense adriamycin/cytoxan followed by taxol. Chemotherapy can have many side effects and can increase risk of hospitalization due to complications. In addition, the financial cost can be considerable. Four cycles of TC will approximately cost $59,000, and most patients likely receive doses of growth factor support (neulasta is $12,565 per dose), totaling at minimum to $100,000 per patient. The purpose of this study was to look at the impact of RxPONDER on our patients. We reviewed patients who had RS at our institution in the last 5 years to see if we were appropriately treating patients with chemotherapy and hormonal therapy, or if a large group could be treated with hormonal therapy alone. Methods: This was an IRB approved retrospective chart review of patients at an academic-community hospital from 2015-2019. We identified patients ≥50 years old diagnosed with ER+/HER2- node positive breast cancer. Exclusion criteria included: M1, pN2, pN3. Univariate analysis used to compare patients that had RS vs those that did not. Student’s t-test was used to analyze whether there was a difference in rate of patients getting chemotherapy based on RS. Results: 216 patients were identified with ER+/Her2- breast cancer and 1-3 positive lymph nodes. 142 had RS (65.7%). Of those with RS, 140 were T1-T2 (98.6%), 131 had 1-2 positive LNs (92.3%), 115 had RS≤25 (80.9%), and 56 received chemotherapy (39.4%). Of the 74 patients without RS, 60 were T1-T2 (94.6%), 69 had 1-2 positive LNs (93.2%), and 51 received chemotherapy (68.9%). 30 patients who met the RxPONDER criteria (postmenopausal, 1-3 positive lymph nodes, and RS ≤25) still received chemotherapy. Conclusions: If we apply the RxPONDER trial recommendations, 30 patients would have been spared chemotherapy. In addition, 54.2% RxPONDER patients had RS ≤25. Extrapolated by percentage, 40 of the 74 patients who did not get RS in our study may have also been spared the side effects and cost of chemotherapy. This would be a savings of at least $3-7 million dollars to the health care system. RxPONDER makes a significant impact, not only in appropriately deescalating breast cancer treatment, but also to counter the increasing cost of medical care.[Table: see text]

Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment

2019 ◽  
Vol 213 (4) ◽  
pp. 953-957 ◽  
Author(s):  
Heather I. Greenwood ◽  
Jasmine M. Wong ◽  
Rita A. Mukhtar ◽  
Michael D. Alvarado ◽  
Elissa R. Price
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Preoperative Localization ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Magnetic Seeds

The Sentinel Lymph Node in T1N0 Breast Cancer

2000 ◽  
Vol 86 (4) ◽  
pp. 327-328 ◽  
Author(s):  
Gian Paolo de Rubeis ◽  
Alberto Bafile ◽  
Valter Resta ◽  
Roberto Vicentini
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Nodes ◽  
Cancer Treatment ◽  
Histological Examination ◽  
Axillary Dissection ◽  
Breast Cancer Treatment ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph

The authors report their experience gathered from December 1998 to December 1999 in the use of the sentinel lymph node (SN) method in breast cancer treatment. In 20 out of 21 cases (95%) localization of the SN was obtained by scintigraphy while in 19 cases (90.5%) the SN was found during surgery. Histological examination of the axillary lymph nodes gave a 95% accuracy with only one negative SN associated with positive axillary lymph nodes out of a total of 19. However, the authors have subjected all patients to a complete three-level axillary dissection since they believe the method applied has not yet been fully validated.

Sign in / Sign up

Export Citation Format

Share Document